CREBBP and EP300 are frequently targeted by loss of function mutations in B/T-ALL [52–54], or rearranged with KMT2A or zinc finger protein 384 (ZNF384) [55, 56]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.